XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Xeris Biopharma Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.95+0.64 (+6.21%)
Close on Oct 19, 2026
- Market cap
- $1.89B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.71 (+18.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Xeris Biopharma Holdings, Inc. grew revenue 36.3% to $335.41M over the twelve months to Jun 30, 2026.
Revenue
$335.41M
+36.3% vs. a year earlier
Operating income
$36.59M
TTM Q2 2026
EPS, diluted
-$0.12
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.89B
- P/E ratio
- –
- Price to sales
- 5.64
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $335.41M
- Net income
- -$17.17M
- EPS, diluted
- -$0.12
- Book value per share
- -$0.06
- Diluted shares
- 173M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$335.41M+36.3% YoY
Gross profit
$290.39M+43.5% YoY
Operating income
$36.59M
Net income
-$17.17M
EPS, diluted
-$0.12
Free cash flow
–
Reported periodTrailing twelve months